BioCentury
ARTICLE | Clinical News

MediciNova, Kyorin preclinical data

February 17, 2014 8:00 AM UTC

In a mouse model of NASH, once-daily 10, 30 and 100 mg/kg doses of oral MN-001 for 3 weeks significantly and dose-dependently reduced fibrosis area vs. vehicle-treated controls (p<0.01). MN-001 also s...